Sanofi experiencing serious supply problems from its Russian plant to EU market

French drugmaker Sanofi (Euronext: SAN) is experiencing serious problems in Russia, as due to logistical problems, the company almost stopped exporting insulin from its Russian plant to the European Union, which was one of the main conditions of the special investment contract (SPIC) with the Russian state, which involves the provision of serious tax benefits for the company, reports The Pharma Letter’s local correspondent.

According to Russian Kommersant business paper, citing RNC Pharma, the Russian pharma analytics agency, in 2022–2023, Sanofi practically did not ship insulin produced at the company’s plant in the Oryol region abroad; the last large deliveries were in 2021 to Germany, where 2 million packages were sent.

Earlier, Sanofi Russia corporate relations director Yuri Mochalin told the Russian media that additional volumes of the drug were supplied to Germany. According to him, now the Oryol Sanofi Vostok plant has focused on supplies to the domestic market due to current logistics problems.